CB1 Receptor Blockers Show Promise for Obesity: Early Trial Results Show Weight Loss and Metabolic Improvement | Research

The takeaway

Review of cannabinoid appetite research confirmed CB1 receptor activation drives increased food intake, and the CB1 blocker rimonabant showed significant weight loss, reduced waist circumference, and improved metabolic markers in early Phase III obesity trials.

Read this if you want to understand the science behind cannabinoid-based approaches to weight management.

Rimonabant showed significant reductions in body weight, waist circumference, and metabolic markers in Phase III

What the researchers found

This review compiled evidence on how cannabinoids regulate eating behavior, covering both exogenous (plant-derived) and endogenous cannabinoids. In multiple species including humans, cannabinoid administration leads to robust increases in food intake and can promote weight gain, mediated through CB1 receptor activation.

Selective CB1 receptor antagonists demonstrated reductions in food intake and body weight with repeated administration. Weight loss was greater in obese animals than lean ones, suggesting the endocannabinoid system is more active in obesity. The reductions appeared to result from dual effects on both food intake and metabolic processes.

The most advanced CB1 antagonist, rimonabant (Acomplia/SR-141716), showed significant reductions in body weight, waist circumference, and improvements in lipid and glucose metabolism in early Phase III results with overweight and obese humans.

Why it matters

This review captured the excitement around rimonabant as a potentially transformative obesity treatment. The dual mechanism of action, reducing both appetite and metabolic dysfunction, was particularly promising for addressing the complex pathophysiology of obesity.

The numbers in context

CB1 antagonists produced greater weight loss in obese vs. lean animals. Rimonabant Phase III results: significant reductions in body weight and waist circumference, improved lipid and glucose metabolism in overweight/obese humans. Dual mechanism: appetite reduction + metabolic improvement.

How the study worked

Narrative review examining evidence from animal behavioral studies, receptor pharmacology, and early Phase III clinical trial data on cannabinoid regulation of food intake and body weight. Covered both agonist (appetite-stimulating) and antagonist (appetite-suppressing) effects.

What this study cannot tell us

The review was published before full Phase III safety data was available. The optimistic tone did not anticipate the psychiatric side effects that later emerged. Animal data showing greater effects in obese subjects may not directly translate to human outcomes.

How to read the evidence

Review incorporating animal data and early Phase III clinical trial results. Full long-term safety data was not yet available at publication.

When this study was published

Published in 2005. Rimonabant was approved in Europe (2006) but withdrawn (2008) due to psychiatric side effects. Research into safer CB1 modulators continues.

The bigger picture

Rimonabant was approved in Europe in 2006 but withdrawn in 2008 due to increased rates of depression and suicidal ideation. Despite this setback, the underlying science about endocannabinoid involvement in appetite and metabolism remains valid and continues to inform drug development for metabolic disorders.

Questions still open

Can peripherally-restricted CB1 antagonists (that do not cross the blood-brain barrier) provide metabolic benefits without psychiatric side effects? What role does the endocannabinoid system play in maintaining obesity once established?

Common questions

Can blocking the cannabinoid system help with weight loss?

Yes. This review showed that CB1 receptor blockers reduced both appetite and body weight, with additional metabolic benefits. The drug rimonabant demonstrated these effects in human trials, though it was later withdrawn due to side effects.

Why would the cannabinoid system be more active in obesity?

Animal research showed that genetically obese animals have an overactive endocannabinoid system, and CB1 blockers produce greater weight loss in obese animals than lean ones. This suggests the endocannabinoid system may be part of a feedback loop that helps maintain obesity once established.

Read the original research

Cannabinoids and the regulation of ingestive behaviour.

Current drug targets, 6(2), 215-23

View on PubMed ↗

Citation

Vickers, S P; Kennett, G A. (2005). Cannabinoids and the regulation of ingestive behaviour.. Current drug targets, 6(2), 215-23.